Drugs / NMRC-M3V-D-PfCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03341754 | Sep 2018 → Oct 2019 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NMRC-M3V-D-PfCA | “Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA” NCT03341754 ↗ |
| Known as | D-CA | “Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA” NCT03341754 ↗ |
| Route | Intramuscular | “as two 1 mL IM injections of the blended D-CA” NCT03341754 ↗ |